PT - JOURNAL ARTICLE AU - Belén Ruiz-Antorán AU - Aránzazu Sancho-López AU - Ferran Torres AU - Víctor Moreno-Torres Concha AU - Itziar de Pablo López de Abechuco AU - Paulina García López AU - Francisco Abad-Santos AU - Clara María Rosso Fernández AU - Ana Aldea-Perona AU - Eva Montané AU - Ruth M. Aparicio-Hdez AU - Roser LLop Rius AU - Consuelo Pedrós AU - Paloma Gijón AU - Carolina Hernández Carballo AU - María José Pedrosa Martínez AU - Consuelo Rodríguez Jiménez AU - Guillermo Prada-Ramallal AU - Lourdes Cabrera García AU - Josefa Andrea Aguilar García AU - Rocío Sanjuan-Jimenez AU - Evelyn Iveth Ortiz Barraza AU - Enrique Sánchez-Chica AU - Ana Fernández-Cruz AU - on behalf of the TOCICOV-study group TI - COMBINATION OF TOCILIZUMAB AND STEROIDS TO IMPROVE MORTALITY IN PATIENTS WITH SEVERE COVID-19 INFECTION: A SPANISH, MULTICENTER, COHORT STUDY AID - 10.1101/2020.09.07.20189357 DP - 2020 Jan 01 TA - medRxiv PG - 2020.09.07.20189357 4099 - http://medrxiv.org/content/early/2020/09/10/2020.09.07.20189357.short 4100 - http://medrxiv.org/content/early/2020/09/10/2020.09.07.20189357.full AB - Background We aimed to determine the impact of tocilizumab use in severe COVID-19 pneumonia mortality.Methods We performed a multicentre retrospective cohort study in 18 tertiary hospitals in Spain, from March to April 2020. Consecutive patients admitted with severe COVID-19 treated with tocilizumab were compared to patients not treated with tocilizumab, adjusting by Inverse Probability of the Treatment Weights (IPTW). Tocilizumab effect in patients receiving steroids during the 48h following inclusion was analyzed.Results During the study period, 506 patients with severe COVID-19 fulfilled inclusion criteria. Among them, 268 were treated with tocilizumab and 238 patients were not. Median time to tocilizumab treatment from onset of symptoms was 11 days (IQR 8-14). Global mortality was 23.7%. Mortality was lower in patients treated with tocilizumab than in controls (16.8% versus 31.5%, HR 0.514 [95CI 0.355-0.744], p< 0.001; weighted HR 0.741 [95CI 0.619-0.887], p = 0.001). Tocilizumab treatment reduced mortality by 14.7% relative to no tocilizumab treatment (RRR 46.7%). We calculated a number necessary to treat of 7. Among patients treated with steroids, mortality was lower in patients treated with tocilizumab than in those treated with steroids alone (10.9% versus 40.2%, HR 0.511 [95CI 0.352-0.741], p = 0.036; weighted HR 0.6 [95CI 0.449-0.804], p< 0.001) (Interaction p = 0.094).Conclusions These results show that survival of patients with severe COVID-19 is higher in patients treated with tocilizumab than in those not treated, and that tocilizumab effect adds to that of steroids administered to non-intubated cases with COVID-19 during the first 48 hours of presenting with respiratory failure despite of oxygen therapy. Randomised controlled studies are needed to confirm these results.Summary We investigated in-hospital mortality of patients with severe SARS-CoV-2 pneumonia in a multicenter series of patients treated with tocilizumab compared to controls, and adjusted using IPTW. Our results show a beneficial impact of tocilizumab treatment in SARS-CoV-2 pneumonia, that adds to that of steroids.Competing Interest StatementThe authors have declared no competing interest.Clinical TrialRegistration: The protocol of the study was registered in EU PAS Register #EUPAS34415 on 31th March 2020 and publicly available at: http://www.encepp.eu/encepp/viewResource.htm?id=35237Clinical Protocols http://www.encepp.eu/encepp/viewResource.htm?id=35237 Funding StatementNo funding was received for this article.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The study was approved by Spanish Agency for Medicine and Health Product and by the Institutional Review Board (CEIm) at Hospital Universitario Puerta de Hierro-Majadahonda (FIB-TOC-2020-01), and a waiver for the informed consent was granted. The study complied with the provisions in European Union (EU) and Spanish legislation on data protection and the Declaration of Helsinki 2013.All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesData sharing: After publication, the data will be made available to others on reasonable requests to the corresponding authors. A proposal with a detailed description of study objectives and statistical analysis plan will be needed for evaluation of the reasonability of requests. Additional materials might also be required during the process of evaluation. De-identified participant data will be provided after approval from the principal researchers of the Hospital Puerta de Hierro-Majadahonda.95CI95% confidence intervalCOPDchronic obstructive pulmonary diseaseCOVID-19coronavirus disease 2019CoVcoronavirusCRPC- reactive proteinCTcomputed tomographyHRhazard ratioICUIntensive care UnitIL-6interleukin-6IPTWinverse probability treatment weightingIQRinterquartile rangeLDHLactate dehydrogenasePaO2/FiO2arterial oxygen tension/inspiratory oxygen fractionDDD-dimerRRRrelative risk reductionSARS-CoVsevere acute respiratory syndrome coronavirusSDstandard deviationSGOT/ASTaspartate aminotransferaseSaO2arterial oxygen saturationSteroidsglucocorticoids or corticoids